Author/Authors :
Peng، نويسنده , , Meiyu and Huang، نويسنده , , Bingqing and Zhang، نويسنده , , Qi and Fu، نويسنده , , Shuyu and Wang، نويسنده , , Dan and Cheng، نويسنده , , Xixi and Wu، نويسنده , , Xi and Xue، نويسنده , , Zhenyi and Zhang، نويسنده , , Lijuan and Zhang، نويسنده , , Da and Da، نويسنده , , Yurong and Dai، نويسنده , , Yun and Yang، نويسنده , , Qing and Yao، نويسنده , , Zhi and Qiao، نويسنده , , Liang and Zhang، نويسنده , , Rongxin، نويسنده ,
Abstract :
Pancreatic cancer is an aggressive malignancy and unresponsive to conventional chemotherapies. Here, the anti-inflammatory and anti-tumor effects of embelin on pancreatic cancer were investigated. Embelin significantly attenuated cells invasion, proliferation and induced apoptosis through inhibition of STAT3 and activation of p53 signaling pathways. Embelin substantially reduced the tumorigenicity of pancreatic cancer cells in vivo, which was associated with reduced inflammatory cells and immune suppressive cells, IL-17A+ Th17, GM-CSF+ Th, MDSCs and Treg, through inhibition of IL-6 secretion. Moreover, embelin decrease IL-6-induced STAT3 phosphorylation. In summary, embelin represents a novel therapeutic drug candidate for the clinical treatment of pancreatic cancer.
Keywords :
IL-6 , pancreatic cancer , MDSCs , inflammation , Embelin
